Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Gilead Sciences (NQ: GILD )

67.81 USD +0.54 (+0.80%)
Streaming Delayed Price Updated: 2:38 PM EST, Jan 28, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 6,851,252
Open 67.37
Bid (Size) 67.81 (2)
Ask (Size) 67.82 (12)
Prev. Close 67.27
Today's Range 67.02 - 68.25
52wk Range 61.39 - 74.12
Shares Outstanding 1,253,809,440
Dividend Yield 4.19%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
FDA Approves Veklury® (Remdesivir) for the Treatment of Non-Hospitalized Patients at High Risk for COVID-19 Disease Progression
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has granted expedited approval of a supplemental new drug application (sNDA) for Veklury®... 
From Business Wire News Releases
Gilead Announces Partial Clinical Hold for Studies Evaluating Magrolimab in Combination With Azacitidine
Gilead Sciences Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has placed a partial clinical hold on studies evaluating the combination of magrolimab plus... 
From Business Wire News Releases

Performance

YTD
-6.57%
-6.57%
1 Month
-7.07%
-7.07%
3 Month
+0.70%
+0.70%
6 Month
-2.89%
-2.89%
1 Year
+3.56%
+3.56%

More News

Read More
Promising Research in Fight Against Breast Cancer Being Amplified by an Active Biotech Sector
Tags Featured News
From FinancialNewsMedia.com Newswire for Stock Alerts, Public Company News Alert
What 5 Analyst Ratings Have To Say About Gilead Sciences
Tags GILD Market News BZI/AAR
From Benzinga
Notable ETF Inflow Detected - HDV, BMY, GILD, LMT
Tags ETFs
From ETF Channel
Nasdaq 100 Movers: ADP, DDOG
Tags Stocks
From Market News Video
The Daily Biotech Pulse: Gilead's Blood Cancer Studies Placed On Partial Clinical Hold, Immunocore Gets FDA Nod, NRx Touts Positive COVID-19 Data
Tags VRTX IBB MNOV
From Benzinga
FDA Puts Clinical Hold On Gilead's Magrolimab/Azacitidine Combo Trials In Blood Cancer Settings
Tags Health Care Briefs Biotech
From Benzinga
FDA Rescinds Authorization For Regeneron, Eli Lilly COVID-19 Antibody Treatments: Here's Why
Tags REGN Omicron Market News
From Benzinga
A Peek Into The Markets: US Stock Futures Down Following Friday's Plunge
Tags Market News GILD News
From Benzinga
FDA Approves Gilead's Remdesivir For Non-Hospitalized COVID-19 Patients At High Risk For Disease Progression
Tags Benzinga Briefs Health Care
From Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.